Background: Given the increase in medications for type 2 diabetes mellitus, clinicians and
patients need information about their effectiveness and safety to make informed choices …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …

Objectives: Identify the mechanism of action of GLP-1 receptor agonists. Assess the potential
adverse effects of GLP-1 receptor agonists. Differentiate the proper administration …

Background Glucagon‐like peptide analogues are a new class of drugs used in the
treatment of type 2 diabetes that mimic the endogenous hormone glucagon‐like peptide 1 …

BACKGROUND: Considerable clinical data on the treatment of type 2 diabetes with incretin-
based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl …

Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, and is
associated with a high risk of cardiovascular morbidity and mortality. Intensive control of …

Traditional anti-diabetic drugs may have negative or positive effects on risk of bone
fractures. Yet the relationship between the new class glucagon-like peptide-1 receptor …

Aims New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due
regulatory requirements from the Food and Drug Administration. For this reason, glucagon …

• De streefwaarden van het HbA1c zijn aangepast. De intensiteit van de
diabetesbehandeling, leeftijd van de patiënt en de diabetesduur zijn factoren die van …

Type 2 diabetes mellitus (T2DM) is a worldwide public health challenge. Despite the
availability of many antidiabetes agents and pharmacotherapies targeting cardiovascular …